直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Article

Preparing a Promising Drug Candidate for ANDA Litigation - Part 1

September 3, 2018

Life Science Leader

By Michael J. Flibbert; Megan Leinen Johns

Having a promising drug candidate in clinical trials can be an exciting time for a pharmaceutical company. It is also a time when it pays to think ahead on how best to position that drug candidate for patent coverage and how to withstand likely patent challenges. Most new drugs receive about 12 to 16 years of market exclusivity from the time of FDA approval. With patent protection serving an integral role in maintaining market exclusivity against generic competition, you need to understand how your actions may potentially affect patent coverage and enforcement. In this article Finnegan attorneys Mike Flibbert and Megan Leinen Johns discuss how to prepare a drug candidate for ANDA litigation.

Click here to read the full article. 

Related Practices

Global IP Enforcement, Litigation, and Trials

Branded Hatch-Waxman (ANDA) Litigation and Trials

Related Industries

Life Sciences

Pharmaceutical

Related Offices

Washington, DC

Related Professionals

Michael J. Flibbert
Partner
Washington, DC
+1 202 408 4493
Email

Originally printed in Life Science Leader on September 3, 2018. This article is for informational purposes, is not intended to constitute legal advice, and may be considered advertising under applicable state laws. This article is only the opinion of the authors and is not attributable to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, or the firm's clients.

Related Insights

Conference

2027 ABA-IPL Section Annual Meeting – IPLSPRING

April 14-15, 2027

Arlington

Conference

Patent Litigation Europe 2027

January 18-20, 2027

Amsterdam

Reception

2026 IPO Education Foundation Awards Dinner

December 15, 2026

Washington, DC

Conference

IP Life Sciences Forum 2026

December 13-15, 2026

Coral Gables

Panel Discussion

2026 Advanced Patent Law Institute

December 3-4, 2026

Stanford

Webinar

Data and Market Exclusivity: An Update on China’s New Law and Comparisons to the US and Europe

November 19, 2026

Webinar

Conference

IPBC Asia 2026

November 17-19, 2026

Tokyo

Conference

NAPABA Convention 2026

November 12-14, 2026

Los Angeles

Conference

IAM Live: Trade Secret Strategy USA

November 10, 2026

San Jose

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP